Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an In Vitro infection model

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 2942-2947

  Liang, Wang ^a   Chen, Yuan Cheng ^a   Cao, Yu Ran ^a   Liu, Xiao Fang ^a   Huang, Jun ^a   Hu, Jia Li ^a   Zhao, Miao ^a   Guo, Qing Lan ^a   Zhang, Shu Jing ^a   Wu, Xiao Jie ^a   Zhu, De Mei ^a   Zhang, Ying Yuan ^a   Zhang, Jing ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEMONOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG EFFICACY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; QUINOLONES; STREPTOCOCCUS PNEUMONIAE;

EID: 84879022227     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01098-12     Document Type: Article

References (26)

1. Roychoudhury S, Twinem TL, Makin KM, McIntosh EJ, Ledoussal B, Catrenich CE. 2001. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae. J. Antimicrob. Chemother. 48:29-36. (Pubitemid 32684722)
2. Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG. 2009. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob. Agents Chemother. 53:4915-4920.
3. Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagace-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Karlowsky JA, Walkty A, Schweizer F, Johnson J, Hoban DJ. 2010. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob. Agents Chemother. 54:4684-4693.
4. Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR. 2009. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J. Antimicrob. Chemother. 64:1226-1229.
5. Guo B, Zhang J, Yu J, Wu X, Shi Y, Tsai CY. 2012. A liquid chromatography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharmacokinetic study in healthy Chinese volunteers. Biomed. Chromatogr. 26:1333-1340.
6. van Rensburg DJ, Perng RP, Mitha IH, Bester AJ, Kasumba J, Wu RG, Ho ML, Chang LW, Chung DT, Chang YT, King CH, Hsu MC. 2010. Efficacy and safety of nemonoxacin versus levofloxacin for communityacquired pneumonia. Antimicrob. Agents Chemother. 54:4098-4106.
7. Rybak MJ, Allen GP, Hershberger E. 2002. In vitro antibiotic pharmacodynamic models, p 41-65. In Nightingale CH, Murakawa T, Ambrose PG (ed), Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker, New York, NY.
8. Dudley MN, Griffith D. 2002. Animal models of infection for the study of antibiotic pharmacodynamics, p 67-98. In Nightingale CH, Murakawa T, Ambrose PG (ed), Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker, New York, NY.
9. Gloede J, Scheerans C, Derendorf H, Kloft C. 2010. In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J. Antimicrob. Chemother. 65:186-201.
10. CLSI. 2011. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI M100-S21. CLSI, Wayne, PA.
11. Grasso S, Meinardi G, de Carneri I, Tamassia V. 1978. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob. Agents Chemother. 13:570-576. (Pubitemid 8321200)
12. Sevillano D, Aguilar L, Alou L, Gimenez MJ, Echevarria O, Cafini F, Valero E, Fenoll A, Prieto J. 2006. Effects of antimicrobials on the competitive growth of Streptococcus pneumoniae: a pharmacodynamic in vitro model approach to selection of resistant populations. J. Antimicrob. Chemother. 58:794-801. (Pubitemid 44390955)
13. Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL. 2007. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:3988-4000. (Pubitemid 350057798)
14. Guo B, Wu X, Zhang Y, Shi Y, Yu J, Cao G, Zhang J. 2012. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin. Drug Invest. 32:475-486.
15. Lin L, Chang LW, Tsai CY, Hsu CH, Chung DT, Aronstein WS, Ajayi F, Kuzmak B, Lyon RA. 2010. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob. Agents Chemother. 54:405-410.
16. Firsov AA, Vostrov SN, Shevchenko AA, Cornaglia G. 1997. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob. Agents Chemother. 41:1281-1287. (Pubitemid 27231427)
17. Bowker KE, Noel AR, MacGowan AP. 2009. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J. Antimicrob. Chemother. 64: 1044-1051.
18. Boak LM, Li J, Rayner CR, Nation RL. 2007. Pharmacokinetic/ pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob. Agents Chemother. 51:1287-1292. (Pubitemid 46586807)
19. Sevillano D, Aguilar L, Alou L, Gimenez MJ, Gonzalez N, Torrico M, Cafini F, Garcia-Rey C, Garcia-Escribano N, Prieto J. 2010. Exposureresponse analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. Int. J. Antimicrob. Agents 36:137-144.
20. Marrie TJ. 1998. Community-acquired pneumonia: epidemiology, etiology, treatment. Infect. Dis. Clin. North Am. 12:723-740. (Pubitemid 28461427)
21. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44: S27-S72. (Pubitemid 46290553)
22. Memish ZA, Osoba AO, Shibl AM, Mokaddas E, Venkatesh S, Rotimi VO. 2007. Emergence and trends of penicillin non-susceptible Streptococcus pneumoniae in Saudi Arabia and Kuwait-perspective and outstanding issues. J. Chemother. 19:471-481. (Pubitemid 350177956)
23. Sunagawa S, Fujita J, Higa F, Tateyama M, Haranaga S, Nakasone I, Yamane N, Uno T. 2011. Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong. J. Antibiot. (Tokyo) 64:539-545.
24. Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH. 2010. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob. Agents Chemother. 54:1338-1342.
25. Scaglione F, Mouton JW, Mattina R, Fraschini F. 2003. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob. Agents Chemother. 47:2749-2755. (Pubitemid 37040243)
26. Lemaire S, Kosowska-Shick K, Appelbaum PC, Glupczynski Y, Van Bambeke F, Tulkens PM. 2011. Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and cotrimoxazole and attempt at defining an intracellular susceptibility breakpoint. J. Antimicrob. Chemother. 66:596-607.